August 25th 2025
An FDA Form 483 cited unaddressed contamination, pest infestations, and equipment failures at manufacturer’s Bloomington, IN facility, which was acquired in the Catalent buyout.
Pharma Cold Chain: Pushing the Envelope
September 23rd 2021The pressure is on for stakeholders to continue pioneering novel engineering designs, insulation options and advanced monitoring and data analytics tools—to meet the complex demands of today’s temperature-controlled products while keeping costs low